Neurofilaments in pre-symptomatic ALS and the impact of genotype

References

• Sperling RA, Rentz DM, Johnson KA, Karlawish J, Donohue M, Salmon DP, Aisen P. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs13.
   PubMed Web of Science ®Google Scholar
• Preische O, Schultz SA, Apel A, Kuhle J, Kaeser SA, Barro C, et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med. 2019;25:277–83.
   PubMed Web of Science ®Google Scholar
• Weston PSJ, Poole T, O’Connor A, Heslegrave A, Ryan NS, Liang Y, et al. Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer’s disease. Alzheimers Res Ther. 2019;11:19.
   PubMed Web of Science ®Google Scholar
• Weston PSJ, Poole T, Ryan NS, Nair A, Liang Y, Macpherson K, et al. Serum neurofilament light in familial Alzheimer disease: a marker of early neurodegeneration. Neurology. 2017;89:2167–75.
   PubMed Web of Science ®Google Scholar
• Rostgaard N, Roos P, Portelius E, Blennow K, Zetterberg H, Simonsen AH, et al. CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers. Neurology. 2018;90:e157–63.
   PubMed Web of Science ®Google Scholar
• Scherling CS, Hall T, Berisha F, Klepac K, Karydas A, Coppola G, et al. Cerebrospinal fluid neurofilament concentration reflects disease severity in frontotemporal degeneration. Ann Neurol. 2014;75:116–26.
   PubMed Web of Science ®Google Scholar
• Meeter LH, Dopper EG, Jiskoot LC, Sanchez-Valle R, Graff C, Benussi L, et al. Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol. 2016;3:623–36.
   PubMed Web of Science ®Google Scholar
• Byrne LM, Rodrigues FB, Blennow K, Durr A, Leavitt BR, Roos RAC, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol. 2017;16:601–9.
   PubMed Web of Science ®Google Scholar
• Vinther-Jensen T, Bornsen L, Budtz-Jorgensen E, Ammitzbøll C, Larsen IU, Hjermind LE, et al. Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol Neuroimmunol Neuroinflamm. 2016;3:e287.
   PubMed Web of Science ®Google Scholar
• Wild E, Tabrizi S. Premanifest and early Huntington’s disease. In: Bates G, Tabrizi S, Jones L, eds. Huntington’s disease. New York: Oxford University Press; 2014; 86–106.
   Google Scholar
• Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A. Neurofilament light: a candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion. Ann Neurol. 2018;84:130–9.
   PubMed Web of Science ®Google Scholar
• Lu C-H, Petzold A, Topping J, Allen K, Macdonald-Wallis C, Clarke J, et al. Plasma neurofilament heavy chain levels and disease progression in amyotrophic lateral sclerosis: insights from a longitudinal study. J Neurol Neurosurg Psychiatry. 2015;86:565–73.
   PubMed Web of Science ®Google Scholar
• Zucchi E, Lu C-H, Cho Y, Chang R, Adiutori R, Zubiri I, et al. A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry. J Neurochem. 2018;146:631–41.
   PubMed Web of Science ®Google Scholar
• Benatar M, Wuu J. Presymptomatic studies in ALS: rationale, challenges, and approach. Neurology. 2012;79:1732–9.
   PubMed Web of Science ®Google Scholar
• Abrahams S, Newton J, Niven E, Foley J, Bak TH. Screening for cognition and behaviour changes in ALS. Amyotrophic Lateral Scler Frontotemporal Degener. 2014;15:9–14.
   PubMed Web of Science ®Google Scholar
• Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, et al. Amyotrophic lateral sclerosis – frontotemporal spectrum disorder (ALS-FTSD): revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18:153–74.
   PubMed Web of Science ®Google Scholar
• Benatar M, Turner M, Wuu J. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:303–9.
   PubMed Web of Science ®Google Scholar
• De Schaepdryver M, Jeromin A, Gille B, Claeys KG, Herbst V, Brix B, et al. Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018;89:367–73.
   PubMed Web of Science ®Google Scholar
• Wild EJ, Petzold A, Keir G, Tabrizi SJ. Plasma neurofilament heavy chain levels in Huntington’s disease. Neurosci Lett. 2007;417:231–3.
   PubMed Web of Science ®Google Scholar
• Meeter LHH, Gendron TF, Sias AC, Jiskoot LC, Russo SP, Donker Kaat L, et al. Poly(GP), neurofilament and grey matter deficits in C9orf72 expansion carriers. Ann Clin Transl Neurol. 2018;5:583–97.
   PubMed Web of Science ®Google Scholar
• Weydt P, Oeckl P, Huss A, Müller K, Volk AE, Kuhle J, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann Neurol. 2016;79:152–8.
   PubMed Web of Science ®Google Scholar
• Poesen K, De Schaepdryver M, Stubendorff B, Gille B, Muckova P, Wendler S, et al. Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology. 2017;88:2302–9.
   PubMed Web of Science ®Google Scholar
• Adiutori R, Aarum J, Zubiri I, Bremang M, Jung S, Sheer D, et al. The proteome of neurofilament-containing protein aggregates in blood. Biochem Biophys Rep. 2018;14:168–77.
   PubMedGoogle Scholar
• Benatar M, Polak M, Kaplan S, Glass J. Preventing familial amyotrophic lateral sclerosis: is a clinical trial feasible? J Neurol Sci. 2006;251:3–9.
   PubMed Web of Science ®Google Scholar
• Benatar M, Polak M, Feng R. Predicting the risk of disease in familial amyotrophic lateral sclerosis. American Neurological Association 133rd Annual Meeting, Salt Lake City, 2008.
   Google Scholar
• Langbehn DR, Hayden MR, Paulsen JS. CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches. Am J Med Genet. 2010;153B:397–408.
   PubMed Web of Science ®Google Scholar
• Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, et al. Symptom onset in autosomal dominant Alzheimer disease: a systematic review and meta-analysis. Neurology. 2014;83:253–60.
   PubMed Web of Science ®Google Scholar